GlobeNewsWire
27 Mar 2026, 11:00 UTC · 25w ago
Verdict
Headline takes no side. We score EDIT +0.80 across four claims — strongly bullish.
+0.80strongly bullish
More positive than 85% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
The U.S. Patent and Trademark Office reaffirmed a decision favoring the Broad Institute in a CRISPR/Cas9 patent interference against CVC.
More positive than 92% of claims this week
Editas Medicine holds the exclusive license for the CRISPR/Cas9 patents at issue for the development and commercialization of human medicines.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 77% of claims this week
Editas is developing EDIT-401, which has demonstrated over 90 percent mean LDL cholesterol reduction in non-human primates.
More positive than 63% of claims this week
The CVC group retains the right to appeal the PTAB's decision to the U.S. Court of Appeals for the Federal Circuit.
More negative than 71% of claims this week
Which stocks this story touches
More positive than 85% of ticker scores this week
The company received a favorable USPTO decision reaffirming the patent priority of the Broad Institute, which Editas exclusively licenses.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
5h ago
+18.6%
Price agrees with the score
$2.75 vs $2.32 close before publication (Mar 26) · not market-adjusted
EDIT chart →
